ba0007oc7 | (1) | ICCBH2019
Tosi Laura
, Estrada Andrea
, Floor Marianne
, Kim Mirini
, Weigley Lindsay
, Dollar Christina
, Gillies Austin
, Roberts Mary Scott
, Gafni Rachel
, Boyce Alison
Objectives: Bisphosphonates are frequently used in children with skeletal disorders, however optimal dosing and regimens are unknown. Early treatment focused on pamidronate (PAM), a second-generation formulation, however use of zoledronate (ZOL), a more potent third-generation bisphosphonate, has recently increased due to shorter and less frequent infusions. The objective of this study is to compare short-term safety of ZOL and PAM in a pediatric population.<p class="abste...